Investigator Sponsored Phase I/II study of AXL1717 in Patients with Brain Tumors
News Apr 25, 2013
Axelar AB has announced that an investigator sponsored Phase I/II study with AXL1717 in patients with malignant astrocytomas, a type of brain tumor, has commenced in the United States.
The study is conducted at the Rush University Medical Center in Chicago in patients with relapsed or progressive malignant astrocytomas (glioblastoma and anaplastic astrocytoma), with AXL1717 - an oral small-molecule insulin-like Growth Factor 1 (IGF-1) receptor inhibitor - as the investigational drug.
Astrocytoma represents about half of all primary tumors of the brain and spinal cord. The most common malignant brain tumors in adults, glioblastomas, make up about two-thirds of all astrocytomas.
This study is also supported by Voices Against Brain Cancer and Gateway for Cancer Research.
More detailed information about the study can be found on www.clinicaltrials.gov (Identifier: NCT01721577).
Dr. Carl Harald Janson, CEO, Axelar AB “We are very pleased to support this investigator sponsored study in astrocytomas with supply of study drug. Preclinical data supports treatment with AXL1717 in patients with astrocytomas and we now look forward to follow this important clinical study, since treatment for astrocytomas remains very challenging and new advances are necessary to improve clinical outcome.”
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE